P50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance

被引:360
作者
Saccani, Alessandra
Schioppa, Tiziana
Porta, Chiara
Biswas, Subhra K.
Nebuloni, Manuela
Vago, Luca
Bottazzi, Barbara
Colombo, Mario P.
Mantovani, Alberto
Sica, Antonio
机构
[1] Ist Clin Humanitas, IRCCS, I-20089 Milan, Italy
[2] Ist Nazl Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy
[3] Ist Ric Farmacol Mario Negri, Milan, Italy
[4] State Univ Milan, Dept Clin Sci L Sacco, Inst Pathol, Milan, Italy
[5] State Univ Milan, Inst Gen Pathol, Milan, Italy
关键词
D O I
10.1158/0008-5472.CAN-06-1867
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor-associated macrophages (TAM) are a major inflammatory infiltrate in tumors and a major component of the protumor function of inflammation. TAM in established tumors generally have an M2 phenotype with defective production of interleukin-12 (IL-12) and high IL-10. Here, we report that defective responsiveness of TAM from a murine fibrosarcoma and human ovarian carcinoma to M1 activation signals was associated with a massive nuclear localization of the p50 nuclear factor-kappa B (NF-kappa B) inhibitory homodimer. p50 overexpression inhibited IL-12 expression in normal macrophages. TAM isolated from p50(-/-) mice showed normal production of M1 cytokines, associated with reduced growth of transplanted tumors. Bone marrow chimeras showed that p50 inactivation in hematopoietic cells was sufficient to result in reduced tumor growth. Thus, p50 NF-kappa B overexpression accounts for the inability of TAM to mount an effective M1 antitumor response capable of inhibiting tumor growth.
引用
收藏
页码:11432 / 11440
页数:9
相关论文
共 51 条
[1]   NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance [J].
Adib-Conquy, M ;
Adrie, C ;
Moine, P ;
Asehnoune, K ;
Fitting, C ;
Pinsky, MR ;
Dhainaut, JF ;
Cavaillon, JM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1877-1883
[2]   Toll-like receptors and their signaling mechanisms [J].
Akira, S ;
Sato, S .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (09) :555-562
[3]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[4]  
Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO
[5]  
2-4
[6]  
Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101
[7]   Smoldering and polarized inflammation in the initiation and promotion of malignant disease [J].
Balkwill, F ;
Charles, KA ;
Mantovani, A .
CANCER CELL, 2005, 7 (03) :211-217
[8]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[9]   A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation) [J].
Biswas, SK ;
Gangi, L ;
Paul, S ;
Schioppa, T ;
Saccani, A ;
Sironi, M ;
Bottazzi, B ;
Doni, A ;
Vincenzo, B ;
Pasqualini, F ;
Vago, L ;
Nebuloni, M ;
Mantovani, A ;
Sica, A .
BLOOD, 2006, 107 (05) :2112-2122
[10]   Regulation of an essential innate immune response by the p50 subunit of NF-κB [J].
Bohuslav, J ;
Kravchenko, VV ;
Parry, GCN ;
Erlich, JH ;
Gerondakis, S ;
Mackman, N ;
Ulevitch, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (09) :1645-1652